Key result
Chronic administration of losartan in cardiomyopathic hamsters enhanced conduction velocity (49 vs 38 cm/s, p<0.05) and reduced interstitial fibrosis (14% vs 22%, p<0.05).
Why the study?
Does chronic administration of losartan improve gap junction conductance, conduction velocity, and interstitial fibrosis in cardiomyopathic hamsters with failing hearts?
Population
4-month-old cardiomyopathic hamsters (TO-2) with failing hearts
Comparison
Losartan 25 mg/kg/day orally for two months vs Control (untreated cardiomyopathic hamsters)
Design
Preclinical
Follow-up
2 months
Authors
Loading...
Hypothesis-generating in hamsters; leaves open whether losartan improves conduction or fibrosis in human heart failure.
Does chronic administration of losartan improve gap junction conductance, conduction velocity, and interstitial fibrosis in cardiomyopathic hamsters with failing hearts?
Absolute Event Rate: 49% vs 38%
p-value: p=<0.05
Chronic AT1-receptor blockade with losartan improves electrical conduction and reduces fibrosis in a hamster model of heart failure.
Walmor C. De Mello (2006) studied Failing heart (cardiomyopathy). Losartan vs. Control was evaluated on Conduction velocity and interstitial fibrosis (p=<0.05). Chronic administration of losartan in cardiomyopathic hamsters enhanced conduction velocity (49 vs 38 cm/s, p<0.05) and reduced interstitial fibrosis (14% vs 22%, p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: